UTHR's revenue reached $832.5M in 2026Q3, but growth has decelerated to 4.1% year over year from mid-teens rates in 2024 and early 2025, while diluted EPS fell 20.3% to $5.71, suggesting earnings pressure is outpacing the top line.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has slowed to 4.1% in 2026Q3 while operating margin compressed to 37.0% from roughly 48% in mid-2025, suggesting rising R&D (to $279.2M) is absorbing operating leverage.
The completion of the Phase 3 Ralinepag trial in pulmonary arterial hypertension is a key bullish driver for United Therapeutics.
The company's scheduled presentation at the 44th Annual J.P. Morgan Healthcare Conference is expected to highlight growth opportunities.
UTHR's trailing and forward P/E ratios of 17.89 and 15.15 respectively suggest the stock is reasonably valued.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $5.71-5.0% vs $6.01 | $833M+6.6% vs $781M |
Q3 2026 Aug 5, 2026 | $7.27+6.0% vs $6.86 | $783M-2.7% vs $805M |
Q2 2026 May 6, 2026 | $5.82-16.9% vs $7.00 | $782M-2.0% vs $797M |
Q1 2026 Feb 25, 2026 | $7.70+8.0% vs $7.13 | $790M-2.8% vs $813M |
United Therapeutics NASDAQ: UTHR reported record third-quarter 2026 revenue of $833 million, driven in part by record Tyvaso sales of $504 million, while pushing back a planned regulatory submission for its soft mist inhaler to 2027.
United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
United Therapeutics (UTHR) came out with quarterly earnings of $5.71 per share, missing the Zacks Consensus Estimate of $5.85 per share. This compares to earnings of $7.16 per share a year ago.
Benchmark UTHR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for United Therapeutics Corporation (UTHR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $562.02 | $23.86B | 20.69 | 10.61% | 38.61% | 19.18% | — | |
| $31.24 | $2.74B | -7.66 | 3024.43% | -1149.62% | -39.52% | — | |
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | — | — | |
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — | |
| $132.04 | $8.49B | 27.67 | -89.41% | 62.04% | 42.83% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — |
United Therapeutics Corporation (UTHR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
United Therapeutics Corporation (UTHR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Oct 22, 2026·SEC
Oct 14, 2026·SEC
Feb 25, 2026·SEC
Get notified when UTHR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
United Therapeutics Corporation (UTHR) stock FAQ — growth, dividends, profitability & financials explained
United Therapeutics Corporation (UTHR) reported $3.18B in revenue in fiscal year 2025, which is also its trailing twelve months. That is 3182600% more than the $0.1M of fiscal year 1998.
United Therapeutics Corporation (UTHR) grew revenue by 1.9% over the trailing twelve months, compared with the twelve months before.
Yes. United Therapeutics Corporation (UTHR) earned $1.23B in net income over the trailing twelve months (a 38.6% net margin).
United Therapeutics Corporation (UTHR) had a return on equity (ROE) of 19.2% over the trailing twelve months. That is above the market's typical 10-15%.
United Therapeutics Corporation (UTHR) generated $867.2M in free cash flow over the trailing twelve months.
